Testosterone transdermal - Transdermal Delivery Solutions
Alternative Names: Testagen HypoSpray; Testagen TDS; Testosterone spray -Transdermal Delivery SolutionsLatest Information Update: 28 Jun 2022
Price :
$50 *
At a glance
- Originator Transdermal Delivery Solutions Corp
- Developer St. Bartholomews Hospital; Transdermal Delivery Solutions Corp
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hypogonadism
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Hypogonadism(In volunteers) in United Kingdom (Transdermal, Spray)
- 10 Jun 2022 Transdermal Delivery Solutions Corp plans a phase II trial for Hypogonadotropism (Transdermal) in the United Kingdom (NCT01894308)
- 19 Apr 2016 Waiting for QC - MHRA approves CTAs for transdermal testosterone to begin phase III trials in hypogonadism